Company
Stimlabs
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$10.0M
1 Form D offering, 2021 to 2021
Equity
$10.0M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $10.0M raised of $10.0M sought, first sale Dec 6, 2021, 26 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Dec 6, 2021 | Equity | $10.0M | $10.0M | 26 | Rule 506(b) | Form D ↗Dec 21, 2021 |
Company details
From the company's latest Form D.
- Legal name
- Stimlabs LLC
- Headquarters
- Roswell, Georgia
- Incorporated
- Georgia over five years before filing
- Entity type
- Limited Liability Company
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1900728 ↗
Executives, directors and promoters
As listed on the latest Form D.
1 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Stimlabs.
Latest FDA decisions
- Theracor510(k)
K253339 · Decided Dec 22, 2025 · 83 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
K242828 · Decided Oct 18, 2024 · 29 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
K231325 · Decided Feb 2, 2024 · 270 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic WoundsEnrolling by invitation
NCT07414368 · 10 participants (planned) · Start Feb 11, 2026 · Primary completion Jun 2026
Device: Corplex P is used to cover, protect, and provide a moist wound environment · For: Chronic Ulcers; Diabetic Foot Ulcers (DFU); DFU and 1 more
Sites: Bridgeport, Connecticut
- Modified Platform Trial Assessing Multiple Umbilical Cord-based CAMPs and SOC v SOC Alone in the Treatment of Hard-to-Heal DFUsPivotal-lookingNot yet recruiting
NCT07449975 · 272 participants (planned) · Start Jul 2026 · Primary completion Jul 2029
Device: Corplex P; Theracor · For: Diabetic Foot Ulcer (DFU); Ulcer Foot; Diabetic Foot and 1 more
- Modified Platform Trial Assessing Multiple Umbilical Cord-based CAMPs and SOC v SOC Alone in the Treatment of Hard-to-Heal VLUsPivotal-lookingNot yet recruiting
NCT07449988 · 272 participants (planned) · Start Jul 2026 · Primary completion Jul 2029
Device: Corplex P; Theracor · For: Venous Leg Ulcers; Venous Leg Ulcers (VLUs); Venous Leg and 2 more
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.